Structure Therapeutics Inc American Depositary Shares

Yahoo Finance • 23 days ago

Stocks making the biggest moves midday: Novo Nordisk, ServiceNow, Freeport-McMoRan, Structure Therapeutics & more

Check out the companies making headlines in midday trading. ServiceNow — Shares of the software company fell nearly 3% after it said it would acquire cybersecurity startup Armis for $7.75 billion . The deal, which should close next year, w... Full story

Yahoo Finance • last month

Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss

Eli Lilly is putting the "obesity field on notice again," an analyst said Thursday after its next-gen delivered 28.7% weight loss. Continue Reading... Full story

Yahoo Finance • last month

Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7%

Eli Lily rose above a key level after saying its experimental obesity treatment delivered 23.7% weight loss in a late-stage trial. Continue Reading... Full story

Yahoo Finance • last month

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obes... Full story

Yahoo Finance • last month

In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?

In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday. Continue Reading... Full story

Yahoo Finance • last month

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obes... Full story

Yahoo Finance • last month

Structure Therapeutics Soars; CEO Says It Could Have 'Best-In-Class' Weight-Loss Drug

Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients. Continue Reading... Full story

Yahoo Finance • last month

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics Inc. Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight loss up to... Full story

Yahoo Finance • last month

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obes... Full story

Yahoo Finance • 2 months ago

BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts

With significant upside potential, Structure Therapeutics Inc. (NASDAQ:GPCR) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts.BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites U... Full story

Yahoo Finance • 2 months ago

Structure Therapeutics reports Q3 results

* Structure Therapeutics press release [https://seekingalpha.com/pr/20297762-structure-therapeutics-reports-third-quarter-2025-financial-results-and-recent-highlights] (GPCR [https://seekingalpha.com/symbol/GPCR]): Q3 net loss for the th... Full story

Yahoo Finance • 2 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study initiation antic... Full story

Yahoo Finance • 3 months ago

Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks.

Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones. Continue Reading View Comments... Full story

Yahoo Finance • 3 months ago

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

By Bhanvi Satija LONDON (Reuters) -Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war between Novo Nordisk and Pfizer, both vying for access to its pipeline of experi... Full story

Yahoo Finance • 4 months ago

Sum Up The Parts: ONEQ Could Be Worth $97

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 5 months ago

Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill

Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill. Continue Reading View Comments... Full story

Yahoo Finance • 5 months ago

Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying. Continue Reading View Comments... Full story

Yahoo Finance • 5 months ago

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ... Full story

Yahoo Finance • 5 months ago

Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge.

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying. Continue Reading View Comments... Full story

Yahoo Finance • 5 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phas... Full story